Westborough, Massachusetts-based Miach Orthopaedics, Inc., has appointed Patrick McBrayer as president and chief executive officer.
Miach Orthopaedics Names Patrick McBrayer President & CEO
1 min read Premium comments
#miachorthopaedicsSecondary#patrickmcbrayer
McBrayer is a healthcare industry veteran, with over 40 years of experience. He joins Miach Orthopaedics from ACell, Inc., a developer of regenerative medicine products, where he served as president and CEO since 2016.
Over the course of his career, McBrayer has served as president and CEO of several companies including: AxioMed Spine Corporation, a spine technology company; Exogen, Inc., a company focused on musculoskeletal healing; and Osteotech, Inc., a biologics company. He was also the chairman of Adgero Biopharmaceuticals, Inc. and the chairman and chief executive officer for Xylos Corporation, a medical device company focused on biomaterial solutions. McBrayer began his healthcare career at Johnson & Johnson in sales and marketing roles.
McBrayer is a graduate of the United States Military Academy at West Point. Following graduation, he served five years as an infantry company commander in the United States Army.
Miach Orthopaedics is a company focused on creating bio-engineered surgical implants for connective tissue restoration. Its flagship product is the Bridge-Enhanced ACL Restoration (BEAR®) Implant, which treats ACL (anterior cruciate ligament) tears by restoring the soft tissue, rather than reconstruct it.
McBrayer is looking forward to taking Miach’s helm saying in a press announcement, “The team at Miach Orthopaedics has made tremendous progress over the last year in driving market adoption of the BEAR Implant for ACL restoration.”
McBrayer continued, “Surgeons and patients alike understand the benefits of healing a torn ACL rather than replacing it, and I look forward to leading Miach as we work to establish the BEAR Implant as the new standard of care for ACL tear surgery.”
Miach Orthopaedics Vice President and Chief Financial Officer Christopher Joyce had been serving as interim president and CEO since June. Joyce will return to his previous role. He took over as president and CEO when Martha Shadan left the company in June 2022.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.